secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001829126-25-009221
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc Q3 net loss $8.6M ($0.45/diluted); NEO100 Phase 2a shows 21% response rate; board changes
--------------------------------------------------------------------------------

- Net loss of $8.6M ($0.45 diluted EPS) vs $2.2M ($0.12) in Q3 2024; G&A up $903k vs $244k YoY.
- NEO100 Phase 2a in recurrent brain cancer: 21% response rate vs <8% historical; 44% six-month PFS; 33% alive >=18 months.
- NEO212 received FDA authorization to proceed to Phase II; Phase I final cohort dosing on track for Q4 2025.
- NuroMENA subsidiary signed $50M strategic partnership with Quazar Investment, appointed H.H. Sheikh Nahyan as Exec Chairman.
- Dr. Ming-Fu Chiang re-elected to Board after Ishwar K. Puri resigned due to USC objection.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625009221/0001829126-25-009221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625009221/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-009221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer